ELAET (Kearon) 2004

A randomised clinical trial investigating the effect of warfarin versus discontinuation in

1 Treatments

**Studied treatment**
continuation for 2 additional months of warfarin adjusted to achieve a target INR between 2.0 and 3.0.

**Control treatment**
discontinuation (after 1 months)

2 Patients

**Inclusion criteria**
first episode of idiopathic venous thromboembolism; DVT demonstrated by bilateral compression ultrasonography of the proximal leg veins, and (if possible) bilateral impedance plethysmography; PE by ventilation-perfusion lung scan;

**Exclusion criteria**
other indications for, or contraindication to, long-term anticoagulant therapy; need for long-term treatment with nonsteroidal anti-inflammatory drugs, ticlopidine, sulfinpyrazone, dipyridamole, or more than 160 mg of aspirin per day; familial bleeding disorder; major psychiatric disorder; pregnant or could become pregnant

3 Methods

**Blinding**
double blind

**Design**
Parallel groups

**Centers**
13

**Geographical area**
Canada, US

**Sample size**
-18 (-9 / -9 )

**ArretTrt1**
-

**ArretTrt0**
-

**PeriodInclusion**
-

**Hypothese**
-
# 4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
</tr>
</thead>
<tbody>
<tr>
<td>DVT</td>
<td>-/-9</td>
<td>-/-9</td>
</tr>
<tr>
<td>PE (with or without DVT)</td>
<td>-/-9</td>
<td>-/-9</td>
</tr>
<tr>
<td>Incidence of recurrent VTE</td>
<td>3/81</td>
<td>5/84</td>
</tr>
<tr>
<td>Incidence of recurrent VTE (65279;period after cessation of study medication until end of follow-up)</td>
<td>1/81</td>
<td>[0.05; 5.83]</td>
</tr>
<tr>
<td>Mortality (65279;period after cessation of study medication until end of follow-up)</td>
<td>0/84</td>
<td>[0.02; 52.89]</td>
</tr>
<tr>
<td>Mortality</td>
<td>1/81</td>
<td>0/84</td>
</tr>
<tr>
<td>Incidence of major bleeding</td>
<td>0/81</td>
<td>0/84</td>
</tr>
<tr>
<td>Incidence of major bleeding (65279;period after cessation of study medication until end of follow-up)</td>
<td>0/84</td>
<td>[0.02; 52.89]</td>
</tr>
</tbody>
</table>

# 5 References